SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27 | -56.5% | 1,289 | -2.5% | 0.00% | -66.7% |
Q2 2023 | $62 | +12.7% | 1,322 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $55 | +10.0% | 1,322 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $50 | -99.9% | 1,322 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $52,000 | +18.2% | 1,322 | -2.0% | 0.00% | +50.0% |
Q2 2022 | $44,000 | -35.3% | 1,349 | -34.8% | 0.00% | -33.3% |
Q1 2022 | $68,000 | -64.6% | 2,069 | -54.1% | 0.00% | -57.1% |
Q4 2021 | $192,000 | -9.4% | 4,508 | -5.7% | 0.01% | -22.2% |
Q3 2021 | $212,000 | -17.2% | 4,783 | +6.0% | 0.01% | -18.2% |
Q2 2021 | $256,000 | -16.3% | 4,511 | +10.5% | 0.01% | -31.2% |
Q1 2021 | $306,000 | -15.0% | 4,082 | -1.9% | 0.02% | -20.0% |
Q4 2020 | $360,000 | -24.1% | 4,163 | -46.3% | 0.02% | -33.3% |
Q3 2020 | $474,000 | +55.9% | 7,754 | +6.2% | 0.03% | +36.4% |
Q2 2020 | $304,000 | +42.1% | 7,304 | -1.8% | 0.02% | +22.2% |
Q1 2020 | $214,000 | +4.9% | 7,441 | +163.6% | 0.02% | +28.6% |
Q4 2019 | $204,000 | – | 2,823 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |